Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Company Overview

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.66 to $1.77
• 50-Day Range: $2.82 to $59.00
• 52-Week Range: $0.51 to $10.55
• Volume: 211,554 shs
• Average Volume: 3.15 million shs
• Market Capitalization: $12.69 million
• P/E Ratio: 11.40
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANCN Stock Analysis - Frequently Asked Questions

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) announced its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.12.

When did Anchiano Therapeutics IPO?

Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Company Calendar

• Last Earnings: 8/05/2019
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ANCN
• CUSIP: N/A
• CIK: N/A
• Web: www.anchiano.com
• Phone: 857-259-4622
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.46)
• Trailing P/E Ratio: 11.40
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-27,120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 36.08%
• Return on Assets: 27.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.25
• Quick Ratio: 3.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 0.85

Miscellaneous

• Outstanding Shares: 7,420,000
• Free Float: N/A
• Market Cap: $12.69 million
• Optionable: Not Optionable
• Beta: 0.93